IDEAYA Biosciences (NASDAQ:IDYA) Issues Quarterly Earnings Results

Posted by Geri Gentry on Nov 3rd, 2026

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) announced its earnings results on Tuesday. The company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.04), Zacks reports. IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%. The company had revenue of $10.24 million during the quarter, compared to the consensus estimate of $7.58 million. During the same period in the prior year, the firm posted $1.33 earnings per share. The company’s revenue was up 14.6% on a year-over-year basis.

IDEAYA Biosciences Price Performance

Shares of IDYA stock traded up $0.13 during trading hours on Tuesday, reaching $31.77. The company had a trading volume of 212,560 shares, compared to its average volume of 1,018,937. The company has a 50 day moving average of $37.08 and a 200 day moving average of $34.08. The firm has a market cap of $2.79 billion, a price-to-earnings ratio of -16.33 and a beta of -0.04. IDEAYA Biosciences has a 1-year low of $26.81 and a 1-year high of $42.68.

Insider Transactions at IDEAYA Biosciences

In related news, CEO Yujiro Hata sold 26,338 shares of the stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $37.41, for a total value of $985,304.58. Following the sale, the chief executive officer directly owned 690,695 shares in the company, valued at $25,838,899.95. This trade represents a 3.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 4.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on IDYA. Citizens Jmp reissued a “market outperform” rating and issued a $42.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Thursday, October 15th. William Blair initiated coverage on IDEAYA Biosciences in a report on Friday, October 16th. They set an “outperform” rating on the stock. Mizuho set a $44.00 target price on IDEAYA Biosciences in a research note on Thursday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a research report on Tuesday, September 22nd. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, IDEAYA Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $50.55.

View Our Latest Report on IDYA

IDEAYA Biosciences Company Profile

(Get Free Report)

IDEAYA Biosciences, Inc (NASDAQ:IDYA) is a biotechnology company focused on discovering and developing precision medicines for cancer. Its research emphasizes synthetic lethality, biomarker-driven drug discovery and molecularly defined patient populations, with the goal of matching targeted therapies to specific genetic alterations in tumors.

The company’s pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily for genetically defined cancers, including metastatic uveal melanoma.